OLMESARTAN MEDOXOMIL
Olmesartan Medoxomil Adverse Events Reported to the FDA Over Time
How are Olmesartan Medoxomil adverse event reports trending over time?
This graph shows volume of adverse events submitted to the FDA by quarter for Olmesartan Medoxomil, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Olmesartan Medoxomil is flagged as the suspect drug causing the adverse event.
Most Common Olmesartan Medoxomil Adverse Events Reported to the FDA
What are the most common Olmesartan Medoxomil adverse events reported to the FDA?
| Hypotension | 408 (2.13%) |
| Drug Ineffective | 394 (2.05%) |
| Dizziness | 390 (2.03%) |
| Blood Pressure Increased | 308 (1.61%) |
| Diarrhoea | 248 (1.29%) |
| Headache | 233 (1.21%) |
| Renal Failure Acute | 222 (1.16%) |
| Nausea | 213 (1.11%) |
| Oedema Peripheral | 209 (1.09%) |
| Dyspnoea | 188 (.98%) |
| Dehydration | 186 (.97%) |
 Show More |
Share/Embed Graph Export Data
This graph shows the top adverse events submitted to the FDA for Olmesartan Medoxomil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Olmesartan Medoxomil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Adverse Event Categories for Olmesartan Medoxomil
What are the most common Olmesartan Medoxomil adverse events reported to the FDA?
| Neurological | 1132 (5.9%) |
| Cardiac And Vascular Investigations | 823 (4.29%) |
| Decreased And Nonspecific Blood Pre... | 661 (3.45%) |
| Gastrointestinal Signs | 657 (3.42%) |
| Renal Disorders | 639 (3.33%) |
| Therapeutic And Nontherapeutic Effe... | 601 (3.13%) |
| Electrolyte And Fluid Balance Condi... | 568 (2.96%) |
| Epidermal And Dermal Conditions | 566 (2.95%) |
| Respiratory | 517 (2.69%) |
| Cardiac Arrhythmias | 507 (2.64%) |
| Infections - Pathogen Unspecified | 366 (1.91%) |
| Show More |
Share/Embed Graph Export Data
This graph shows the top categories of adverse events submitted to the FDA for Olmesartan Medoxomil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Olmesartan Medoxomil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.
Common Uses of Olmesartan Medoxomil According to Those Reporting Adverse Events
Why are people taking Olmesartan Medoxomil, according to those reporting adverse events to the FDA?
| Hypertension | 6242 |
| Product Used For Unknown Indication | 1084 |
| Drug Use For Unknown Indication | 993 |
| Blood Pressure | 353 |
| Essential Hypertension | 344 |
| Blood Pressure Abnormal | 74 |
| Show More |
Drug Labels
| Label | Labeler | Effective |
|---|---|---|
| Benicar | Physicians Total Care, Inc. | 20-MAY-10 |
| Azor | Physicians Total Care, Inc. | 09-JAN-12 |
| Benicar | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 22-FEB-12 |
| Benicar | Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC | 22-FEB-12 |
| Benicar | PD-Rx Pharmaceuticals, Inc. | 25-APR-12 |
| Benicar | Cardinal Health | 24-SEP-12 |
| Benicar | Daiichi Sankyo, Inc | 12-NOV-12 |
| Tribenzor | Daiichi Sankyo, Inc. | 12-NOV-12 |
| Azor | Daiichi Sankyo, Inc. | 12-NOV-12 |
| Benicar | Med-Health Pharma, LLC | 12-NOV-12 |
| Benicar | Bryant Ranch Prepack | 18-JAN-13 |
| Benicar | Bryant Ranch Prepack | 18-JAN-13 |
Olmesartan Medoxomil Case Reports
What Olmesartan Medoxomil safety concerns are being reported by doctors and researchers in the medical literature?
About Results
This report contains aggregated drug side effects and adverse events for Olmesartan Medoxomil. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.
DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.
DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.
Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.
Comments
Share your experience with Olmesartan Medoxomil.